India, Aug. 7 -- CorMedix Inc. (CRMD), a biopharmaceutical company specializing in life-threatening diseases, Thursday announced a definitive agreement to acquire Melinta Therapeutics, a commercial-stage firm focused on acute and infectious diseases.
The $300 million deal includes $260 million in cash and $40 million in CorMedix equity, with up to $25 million in regulatory milestone payments and royalties on key products REZZAYO and MINOCIN. The transaction is expected to close by September 1, 2025, pending regulatory approval.
The acquisition adds seven marketed hospital- and clinic-based anti-infective drugs to CorMedix's portfolio, including REZZAYO, MINOCIN, VABOMERE, ORBACTIV, KIMYRSA, BAXDELA, and cardiovascular drug TOPROL-XL. Meli...